Versant’s Dayra dawns with $50M Biogen pact, oral macrocyclic peptide mission
VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen. The biopharma has paid…